Home >> Research Area >>Neuroscience>>5-HT Receptor>> (R)-(+)-8-Hydroxy-DPAT hydrobromide

(R)-(+)-8-Hydroxy-DPAT hydrobromide

CAS# 78095-19-9

(R)-(+)-8-Hydroxy-DPAT hydrobromide

2D Structure

Catalog No. BCC6929----Order now to get a substantial discount!

Product Name & Size Price Stock
(R)-(+)-8-Hydroxy-DPAT hydrobromide: 5mg $104 In Stock
(R)-(+)-8-Hydroxy-DPAT hydrobromide: 10mg Please Inquire In Stock
(R)-(+)-8-Hydroxy-DPAT hydrobromide: 20mg Please Inquire Please Inquire
(R)-(+)-8-Hydroxy-DPAT hydrobromide: 50mg Please Inquire Please Inquire
(R)-(+)-8-Hydroxy-DPAT hydrobromide: 100mg Please Inquire Please Inquire
(R)-(+)-8-Hydroxy-DPAT hydrobromide: 200mg Please Inquire Please Inquire
(R)-(+)-8-Hydroxy-DPAT hydrobromide: 500mg Please Inquire Please Inquire
(R)-(+)-8-Hydroxy-DPAT hydrobromide: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of (R)-(+)-8-Hydroxy-DPAT hydrobromide

3D structure

Package In Stock

(R)-(+)-8-Hydroxy-DPAT hydrobromide

Number of papers citing our products

Chemical Properties of (R)-(+)-8-Hydroxy-DPAT hydrobromide

Cas No. 78095-19-9 SDF Download SDF
PubChem ID 11957570 Appearance Powder
Formula C16H26BrNO M.Wt 328.29
Type of Compound N/A Storage Desiccate at -20°C
Solubility Soluble to 75 mM in water and to 75 mM in DMSO
Chemical Name (7R)-7-(dipropylamino)-5,6,7,8-tetrahydronaphthalen-1-ol;hydrobromide
SMILES CCCN(CCC)C1CCC2=C(C1)C(=CC=C2)O.Br
Standard InChIKey BATPBOZTBNNDLN-PFEQFJNWSA-N
Standard InChI InChI=1S/C16H25NO.BrH/c1-3-10-17(11-4-2)14-9-8-13-6-5-7-16(18)15(13)12-14;/h5-7,14,18H,3-4,8-12H2,1-2H3;1H/t14-;/m1./s1
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Biological Activity of (R)-(+)-8-Hydroxy-DPAT hydrobromide

DescriptionFull 5-HT1A serotonin receptor agonist; more active enantiomer. Reduces hippocampal 5-HT levels following systemic administration in rats in vivo. More active enantiomer of 8-Hydroxy-DPAT hydrobromide. 7-Hydroxy-DPAT hydrobromide also available.

(R)-(+)-8-Hydroxy-DPAT hydrobromide Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

(R)-(+)-8-Hydroxy-DPAT hydrobromide Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of (R)-(+)-8-Hydroxy-DPAT hydrobromide

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 3.0461 mL 15.2304 mL 30.4609 mL 60.9217 mL 76.1522 mL
5 mM 0.6092 mL 3.0461 mL 6.0922 mL 12.1843 mL 15.2304 mL
10 mM 0.3046 mL 1.523 mL 3.0461 mL 6.0922 mL 7.6152 mL
50 mM 0.0609 mL 0.3046 mL 0.6092 mL 1.2184 mL 1.523 mL
100 mM 0.0305 mL 0.1523 mL 0.3046 mL 0.6092 mL 0.7615 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University
Featured Products
New Products
 

References on (R)-(+)-8-Hydroxy-DPAT hydrobromide

5-HT1A Receptor Function Makes Wound Healing a Happier Process.[Pubmed:30618734]

Front Pharmacol. 2018 Dec 11;9:1406.

Skin wound healing is a multistage phenomenon that is regulated by cell-cell interplay and various factors. Endogenous serotonin is an important neurotransmitter and cytokine. Its interaction with the serotonin 1A receptor (5-HTR1A) delivers downstream cellular effects. The role of serotonin (5-hydroxytryptamine, 5-HT) and the 5-HT1A receptor has been established in the regeneration of tissues such as the liver and spinal motor neurons, prompting the investigation of the role of 5-HT1A receptor in skin healing. This study assessed the role of 5-HT1A receptor in excisional wound healing by employing an excisional punch biopsy model on 5-Ht1a receptor knockout mice. Post-harvest analysis revealed 5-Ht1a receptor knockout mice showed impaired skin healing, accompanied by a greater number of F4/80 macrophages, which prolongs the inflammatory phase of wound healing. To further unravel this phenomenon, we employed the 5-HT1A receptor agonist [(R)-(+)-8-Hydroxy-DPAT hydrobromide] as a topical cream treatment in an excisional punch biopsy model. The 5-HT1A receptor agonist treated group showed a smaller wound area, scar size, and improved neovascularization, which contributed to improve healing outcomes as compared to the control. Collectively, these findings revealed that serotonin and 5-HT1A receptor play an important role during the healing process. These findings may open new lines of investigation for the potential treatment alternatives to improve skin healing with minimal scarring.

Differential effects of (R)-, (R, S)- and (S)-8-hydroxy-2-(di-n-propylamino)tetralin on hippocampal serotonin release and induction of hypothermia in awake rats.[Pubmed:15050424]

Life Sci. 2004 Apr 23;74(23):2865-75.

The effects of (R)- and (S)-optical isomers of 8-hydroxy-2-(di-n-propylamino)-tetralin (8-OH-DPAT) and of the racemate (R,S)-8-OH-DPAT on serotonin (5-HT) release in the ventral hippocampus of awake rats and on induction of the whole-body hypothermia were studied. Extracellular 5-HT levels were determined by a newly developed high-sensitive HPLC method based on derivatization with benzylamine and fluorescence detection. The basal levels of 5-HT in 20 min microdialysates from rats perfused with Ringer solution or with Ringer solution containing 1 microM citalopram were 6.3 +/- 1.3 fmol/20 microl and 36.1 +/- 4.2 fmol/20 microl (n=20), respectively. The reduction of hippocampal 5-HT levels induced by subcutaneous (s.c.) administration of (R,S)-8-OH-DPAT (0.3 mg/kg) was significantly attenuated by the presence of 5-HT reuptake inhibitor citalopram in Ringer solution only at its peak value at 40 min (maximal reduction to 60% compared to 46% of control values in Ringer-perfused rats), whereas the overall effects were comparable at both experimental conditions. Injection of (R)-8-OH-DPAT (0.3 mg/kg s.c.) caused further reduction of 5-HT levels, to 49% and 41%, respectively, whereas (S)-8-OH-DPAT (0.3 mg/kg s.c.) caused maximal reduction of 5-HT levels only to 74% of controls in both perfusion groups. Similar pattern and time-courses were observed in rats with hypothermia induced by injection of 8-OH-DPAT enantiomers, where (R,S), (R)-forms were about two-times more potent than the (S)-isomer. It is concluded that the acute systemic dose of (R)-, (S)- and (R,S)-8-OH-DPAT enantiomers exerted enantiomer-specific effects on 5-HT(1A) receptor-mediated function both at the presynaptic and postsynaptic sites as revealed by monitoring hippocampal 5-HT levels and body temperature.

Intrinsic activity of enantiomers of 8-hydroxy-2-(di-n-propylamino)tetralin and its analogs at 5-hydroxytryptamine1A receptors that are negatively coupled to adenylate cyclase.[Pubmed:1828859]

Mol Pharmacol. 1991 Jun;39(6):780-7.

Although many different types of compounds have been tested for 5-hydroxytryptamine1A (5-HT1A) binding affinity, much remains to be learned about the structural requirements associated with 5-HT1A agonism, partial agonism, and antagonism. The present study uses the forskolin-stimulated adenylate cyclase (FSC) assay as a functional screen in rat hippocampal membranes to examine structure-activity relationships for a series of enantiomers of novel analogs of the prototypic 5-HT1A agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT). The findings illustrate that there can be large enantiomeric differences in intrinsic activity at the 5-HT1A receptor, independent of enantiomeric effects on binding affinity. Generally, for each enantiomeric pair exhibiting stereoselective 5-HT1A binding, the enantiomer with the higher affinity also displayed the greater amount of 5-HT1A intrinsic activity in the FSC assay. Interestingly, the enantiomers of 8-OH-DPAT itself displayed stereoselective differences in intrinsic activity but not 5-HT1A affinity. Several of the compounds, namely (S)-UH-301, (2R,3R)-CM-12, and (1S,2R)-LEA-146, may have potential as prototypes for selective 5-HT1A antagonists, and (S)-UH-301 itself may be useful as a selective 5-HT1A antagonist. The FSC data presented here are in good agreement with reported measures of in vivo 5-HT1A activity, which were in part the basis of a recently proposed model for the 5-HT1A pharmacophore [J. Med. Chem. 34: 497-510 (1991)].

Resolved N,N-dialkylated 2-amino-8-hydroxytetralins: stereoselective interactions with 5-HT1A receptors in the brain.[Pubmed:2522991]

J Med Chem. 1989 Apr;32(4):779-83.

The enantiomers of the N,N-dimethylamino (1), N,N-diethylamino (2), and N,N-dibutylamino (4) derivatives of 8-hydroxy-2-(dipropylamino)tetralin (8-OH DPAT; 3) have been synthesized. The compounds have been tested for activity at central 5-hydroxytryptamine and dopamine receptors by use of biochemical and behavioral tests in rats. In addition, the ability of the enantiomers of 1-4 to displace [3H]-8-OH DPAT from 5-HT1A binding sites was evaluated. Rank order of potencies in the in vivo tests corresponded to that observed in the 5-HT1A binding assay. In all three tests, the enantiomeric potency ratio was about 10 for 1 and 2 and only around 2-4 for 3 and 4. The more potent enantiomer of 1-3 had the R configuration. In contrast, (S)-4 seemed to be slightly more potent than (R)-4.

Keywords:

(R)-(+)-8-Hydroxy-DPAT hydrobromide,78095-19-9,Natural Products,5-HT Receptor, buy (R)-(+)-8-Hydroxy-DPAT hydrobromide , (R)-(+)-8-Hydroxy-DPAT hydrobromide supplier , purchase (R)-(+)-8-Hydroxy-DPAT hydrobromide , (R)-(+)-8-Hydroxy-DPAT hydrobromide cost , (R)-(+)-8-Hydroxy-DPAT hydrobromide manufacturer , order (R)-(+)-8-Hydroxy-DPAT hydrobromide , high purity (R)-(+)-8-Hydroxy-DPAT hydrobromide

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: